Next generation topoisomerase I inhibitors: Rationale and biomarker strategies

2007/10/29 by Beverly A. Teicher · 5 citations
Biochemistry, Genetics and Molecular Biology · Medicine · Pharmacology, Toxicology and Pharmaceutics · #Bioactive Compounds and Antitumor Agents #Cancer therapeutics and mechanisms #Neutropenia and Cancer Infections

paper · doi:10.1016/j.bcp.2007.10.016

openalex publication_date 2007/10/29 · crossref created 2007/10/29 · crossref issued 2008/03/01 · crossref published 2008/03/01 · crossref published-print 2008/03/01 · crossref deposited 2025/01/22 · openalex created_date 2025/10/10 · crossref indexed 2026/02/07 · openalex updated_date 2026/07/15

Citations

• Bisindenoisoquinoline Bis-1,3-(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylaminopropane bis(trifluoroacetate) (NSC 727357), a DNA Intercalator and Topoisomerase Inhibitor with Antitumor Activity
• Synthesis and Biological Evaluation of Bisindenoisoquinolines as Topoisomerase I Inhibitors
• Optimization of the Indenone Ring of Indenoisoquinoline Topoisomerase I Inhibitors
• Discovery of Antitumor Indolocarbazoles: Rebeccamycin, NSC 655649, and Fluoroindolocarbazoles
• Synthesis and Evaluation of Indenoisoquinoline Topoisomerase I Inhibitors Substituted with Nitrogen Heterocycles
• A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex
• Topoisomerase I inhibitors: camptothecins and beyond

Cited by

• Topoisomerases as anticancer targets
• DNA topoisomerases as molecular targets for anticancer drugs
• Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
• The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives
• Topoisomerase inhibitor [wikipedia]